Comparison of two estradiol transdermal systems (Oesclim® 50 and Estraderm TTS® 50). I. Tolerability, adhesion and efficacy

Maturitas

Volumn 25, Issue 3, 1996, Pages 161-173

  Rozenbaum, Henri ^a   Birkhäuser, Martin ^b   De Nooyer, Coenraad ^c   Lambotte, René ^d   Pornel, Bruno ^a   Schneider, Hermann ^e   Studd, John ^f  

^a Hopital Univ de Gynecologie et d'O ^*  (Belgium)

^b UNIVERSITY OF BERN   (Switzerland)

^c Infection and Immunology   (Netherlands)

^d Centre Hospitalier Regional de La Citadelle   (Belgium)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f LISTER HOSPITAL   (United Kingdom)

Author keywords

estradiol; HRT; menopause; transdermal

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ESTROGEN DEFICIENCY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0030292755     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(96)01068-7     Document Type: Article

References (24)

1. [1] Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol 1977; 4: 31-47.
2. [2] Lindsay R, Hart DM, Aiken JM, MacDonald EB, Anderson JB, Clark AC. Long-term prevention of post-menopausal osteoporosis by oestrogen. Lancet 1976; 1: 1038-1041.
3. [3] Stampfer MJ, Colditz GA, Willett WC et al. Post-menopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991; 325: 756-762.
4. [4] Faguer de Moustier B, Conard J, Guyene, T.T. et al. Comparative metabolic study of percutaneous versus oral micronized 17β estradiol in replacement therapy. Maturitas 1989; 11: 275-286.
5. [5] Judd HL, Cleary RE, Creasman WT et al. Estrogen replacement therapy. Am J Obstet Gynecol 1981; 58: 267-275.
6. [6] De Lignières B, Basdevant A, Thomas G et al. Biological effects of estradiol 17β in post-menopausal women: oral versus percutaneous administration. J Clin Endocrinol Metabol 1986; 62: 536-541.
7. [7] Chetkowski RJ, Meldrum DR, Steingold KA et al. Biologic effect of transdermal estradiol. N Engl J Med 1986; 314: 1615-1620.
8. [8] Estraderm®. Full prescribing information. Physician's Desk Reference, 1993.
9. [9] Padwick ML, Endacott J, Whitehead, MI. Efficacy, acceptability, and metabolic effects of transdermal estradiol in the management of postmenopausal women. Am J Obstet Gynecol 1985; 152: 1085-1091.
10. [10] Place VA, Powers M, Darley PE, et al. A double-blind comparative study of Estraderm and Premarin in the amelioration of post-menopausal symptoms. Am J Obstet Gynecol 1985; 152: 1092-1099.
11. [11] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
12. [12] Rozenbaum H, Birkhauser M, De Nooyer C, Lambotte R, Pornel B, Schneider H, Studd J, Thebault J. Comparison of two estradiol transdermal systems (Oesclim® 50 and Estraderm TTS® 50). II. Local skin tolerability. Maturitas (this issue)
13. [13] Corson, SL. Clinical experience with Systen, a new transdermal form of hormone replacement therapy. Int J Fertil 1993; 38: 36-44.
14. [14] Pornel B, Genazzani AR, Costes D, Dain MP, Lelann L, Vandepol C. Efficacy and tolerability of Menorest® 50 compared with Estraderm® TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study. Maturitas 1995; 22: 207-218.
15. [15] Van Leusden, HAIM, Albertyn, G, Verlaine, C, Van Ruymbeke, J. A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms. Int J Fertil 1993; 38: 210-218.
16. [16] The Transdermal HRT Investigator's Group. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. Int J Fertil 1993; 38: 5-11.
17. [17] Guichard JP, Sauron R, Dutertre JP, Tanner T, Woodward AJ, Dewland PM. A pilot study of the comparative bioavailability of estradiol from two different estradiol transdermal systems: Oesclim® 50 and Systen® 50. Curr Ther Res 1995; 56: 1022-1032.
18. [18] Powers MS, Schenkel L, Darley PE et al. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985; 152: 1099-1106.
19. [19] Stancyzk FZ, Shoupe D, Nunez V, et al. A randomized comparison of non-oral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988; 159: 1540-1546.
20. [20] Marchesoni D, Fiscon D, Bologna A, et al. Transdermal estrogen therapy in menopause: eighteen months follow-up. Clin Exp Obstet Gynecol 1991; 18: 281-285.
21. [21] Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991; 73: 925-930.
22. [22] Miller-Bass K, Adashi EY. Current status and future prospects of transdermal estrogen replacement therapy. Fertil Steril 1990; 53: 961-974.
23. [23] Steingold KA, Laufer L, Chetkowski J, et al. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 1985; 61: 627-632.
24. [24] Haas S, Walsh B, Evans S, Krache M, Ravnikar V, Schiff I. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period. Obstet Gynecol 1988; 71: 671-676.